BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma

Pleural Mesothelioma Malignant Advanced Clinical Trial

— BEAT-meso  

Official title:

A Multicentre Randomised Phase III Trial Comparing Atezolizumab Plus Bevacizumab and Standard Chemotherapy Versus Bevacizumab and Standard Chemotherapy as First-line Treatment for Advanced Malignant Pleural Mesothelioma

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03762018
• Other study ID #: ETOP 13-18
• Secondary ID: 2018-002180-25MO
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: April 30, 2019
• Est. completion date: June 2024

Study information

• Verified date: May 2024
• Source: ETOP IBCSG Partners Foundation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this clinical trial is to assess the effect of treatment with a monoclonal antibody called atezolizumab in patients diagnosed with a type of lung cancer called malignant pleural mesothelioma. The efficacy (whether the treatment works), safety and tolerability (side effects of treatment) of atezolizumab plus bevacizumab in combination with standard chemotherapy versus bevacizumab in combination with standard chemotherapy will be investigated.

Description:

Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer arising from the mesothelial surface of the pleura. In Europe, the incidence is about 20 per million and is almost always caused by asbestos exposure, with a usual lag time of 30 years between exposure and presentation. Patients diagnosed with advanced MPM have limited treatment options, representing a strict unmet need. Despite decades of clinical research, cytotoxic chemotherapy remains one of the few therapeutic options that has been proven to improve survival in advanced MPM in a randomised controlled trial.

The combination of cisplatin and pemetrexed has become standard first-line therapy worldwide for patients who are not suitable for aggressive surgery or in whom chemotherapy is recommended as part of a multimodality regimen. Carboplatin is often substituted for cisplatin, due to simpler and shorter administration and assumption of a more favourable toxicity profile based on experience in other diseases. Patients with MPM have limited treatment options, representing a strict unmet need.

An antibody is a common type of protein usually made in the body in response to a foreign substance. Antibodies attack foreign substances and protect against infection. The two monoclonal antibodies (atezolizumab and bevacizumab) used in this trial are laboratory-produced antibodies. Atezolizumab is engineered to attach to immune cells to stimulate their activity against cancer cells.

Atezolizumab and bevacizumab are both approved by the European Medicines Agency for the treatment of lung and other cancers. The addition of atezolizumab to bevacizumab plus standard chemotherapy for the treatment of MPM is being investigated in this trial.

All participants will receive 4-6 cycles of standard chemotherapy consisting of carboplatin AUC 5 (area under the plasma concentration versus time curve) plus pemetrexed 500mg/m^2 given intravenously, on day 1 of every 3 week cycle for about 12 to 18 weeks.

Participants will be randomly assigned to one of two treatment groups:

Treatment 1

• Bevacizumab 15 mg/kg intravenously on day 1 of every 3-week cycle, plus

• 4-6 cycles of chemotherapy

OR

Treatment 2

• Atezolizumab 1200 mg fixed dose intravenously on day 1 of every 3-week cycle, plus

• Bevacizumab 15 mg/kg, intravenously on day 1 of every 3-week cycle, plus

• 4-6 cycles of chemotherapy

Participants will continue to receive treatment until disease progression, or until treatment is stopped at the request of the participant or treating doctor, or the participant withdraws consent.

A total of 400 participants from approximately 45 centres in Europe are expected to be included in this trial which will take approximately 6 years to be completed after the first participant is enrolled.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 401
• Est. completion date: June 2024
• Est. primary completion date: June 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed advanced malignant pleural mesothelioma (all histological subtypes are eligible)

• Not amenable for radical surgery based on local standards

• Evaluable disease or measurable disease as assessed according to the modified response evaluation criteria for solid tumours for mesothelioma (mRECIST) v1.1

• Availability of tumour tissue for translational research

• Age >18 years

• Performance Status 0-1

• Life expectancy >3 months

• Adequate haematological, renal and liver function

• Completed baseline quality of life (QoL) questionnaire

• Women of childbearing potential and sexually active men must agree to use highly effective contraception

• Able to understand and give written informed consent and comply with trial procedures

Exclusion Criteria:

• Prior treatment for malignant pleural mesothelioma. Prior radiotherapy for symptom control is allowed, but the irradiated lesion cannot be used as target lesion. If the patient has another target lesion, the patient is eligible.

• Treatment with systemic immune-stimulatory agents within 4 weeks or five half-lives of the drug prior to randomisation and during protocol treatment.

• Treatment with systemic immunosuppressive medications within 2 weeks prior to randomisation and during protocol treatment.

• Previous allogeneic tissue/solid organ transplant

• Live vaccines within 4 weeks prior to first dose of protocol treatment

• Inadequately controlled hypertension

• Prior history of hypertensive crisis or hypertensive encephalopathy

• Significant vascular disease within 6 months prior to randomisation

• History of haemoptysis

• Evidence of bleeding diathesis or coagulopathy

• Active autoimmune disease that has required systemic treatment in past 2 years

• History of active diverticulitis

• Previous treatment with atezolizumab and/or bevacizumab or parallel participation in other interventional clinical trial with atezolizumab and/or bevacizumab.

Related Conditions & MeSH terms

• Mesothelioma
• Mesothelioma, Malignant
• Pleural Mesothelioma Malignant Advanced

Intervention

Drug:
• Carboplatin
Carboplatin belongs to the group of medicines known as alkylating agents. Carboplatin interferes with the growth of cancer cells, which eventually are destroyed.
• Pemetrexed
Pemetrexed is a type of drug known as an anti metabolite. It stops cells making and repairing DNA so they can't grow and multiply.
• Bevacizumab
Bevacizumab is an angiogenesis inhibitor. It works by targeting a protein called vascular endothelial growth factor (VEGF) that helps cancers form new blood vessels. By stopping this process, bevacizumab 'suffocates' the blood supply to the cancer, shrinking it and stopping it from growing.
• Atezolizumab
Atezolizumab is in a class of medications called monoclonal antibodies. It works by blocking the action of a certain protein in cancer cells. This helps the immune system to fight against the cancer cells, and helps to slow tumor growth.

Locations

Country	Name	City	State
Belgium	University Hospital Leuven	Leuven
Belgium	CHU Liege	Liege
France	Unicancer - Institut Bergonie	Bordeaux
France	Caen- CHU	Caen
France	Le Mans - CHG	Le Mans
France	Lyon - Centre Léon Bérard	Lyon
France	Hospital Nord	Marseille
France	Curie Cancer Center Paris	Paris
France	Toulouse - CHU	Toulouse
France	Tours - CHU	Tours
Italy	SS Antonio e Biagio e Cesare Arrigo Hospital	Alessandria
Italy	IRCCS Instituto Tumori Giovanni Paolo II	Bari
Italy	Fondazione IRCCS Istituto Nazionale die Tumori	Milan
Italy	Instituto Europeo di Oncologia (IEO)	Milan
Italy	AULSS2 Marca Trevigiana Treviso	Treviso
Italy	University Hospital of Turin	Turin
Spain	Alicante University Hospital ISABIAL	Alicante
Spain	ICO Hospitalet	Barcelona
Spain	Vall Hebron University Hospital/Vall Hebron Institue Oncology	Barcelona
Spain	Puerta de Hierro Hospital	Majadahonda
Spain	Hospital Parc Tauli Sabadell	Sabadell
Spain	Virgen del Rocio	Seville
Spain	Complexo Hospitalario Universitario de Vigo	Vigo
Switzerland	Kantonsspital Aarau	Aarau
Switzerland	Istituto Oncologica della Svizzera Italiana	Bellinzona
Switzerland	Ferdinando Cerciello	Bern
Switzerland	Kantonsspital Graubünden	Chur
Switzerland	CHUV	Lausanne
Switzerland	Luzerner Kantonsspital	Lucerne
Switzerland	Kantonsspital St. Gallen	Saint Gallen
Switzerland	Kantonsspital Winterthur	Winterthur
Switzerland	UniversitätSpital Zürich	Zürich
United Kingdom	Addenbrooke's Hospital	Cambridge
United Kingdom	Clatterbridge Cancer Centre	Liverpool
United Kingdom	Guy's and St Thomas' Hospital	London
United Kingdom	Royal Marsden Hospital (Fulham Road)	London
United Kingdom	Royal Marsden Hospital (Sutton)	London
United Kingdom	Kent Oncology Centre	Maidstone
United Kingdom	Wythenshawe Hospital	Manchester
United Kingdom	Plymouth Hospitals NHS Trust	Plymouth
United Kingdom	Weston Park Hospital	Sheffield
United Kingdom	Royal Cornwall Hospital	Truro

Sponsors (2)

Lead Sponsor	Collaborator
ETOP IBCSG Partners Foundation	Hoffmann-La Roche

Countries where clinical trial is conducted

Belgium,  France,  Italy,  Spain,  Switzerland,  United Kingdom, 

References & Publications (10)

Armato SG 3rd, Nowak AK. Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1). J Thorac Oncol. 2018 Jul;13(7):1012-1021. doi: 10.1016/j.jtho.2018.04.034. Epub 2018 May 9. Erratum In: J Thorac Oncol. 2019 Mar;14(3):560. — View Citation

Ceresoli GL, Zucali PA, Mencoboni M, Botta M, Grossi F, Cortinovis D, Zilembo N, Ripa C, Tiseo M, Favaretto AG, Soto-Parra H, De Vincenzo F, Bruzzone A, Lorenzi E, Gianoncelli L, Ercoli B, Giordano L, Santoro A. Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. Br J Cancer. 2013 Aug 6;109(3):552-8. doi: 10.1038/bjc.2013.368. Epub 2013 Jul 16. — View Citation

Fennell DA, Gaudino G, O'Byrne KJ, Mutti L, van Meerbeeck J. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol. 2008 Mar;5(3):136-47. doi: 10.1038/ncponc1039. — View Citation

Melero I, Berman DM, Aznar MA, Korman AJ, Perez Gracia JL, Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer. 2015 Aug;15(8):457-72. doi: 10.1038/nrc3973. — View Citation

Nowak AK. Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future. Ann Cardiothorac Surg. 2012 Nov;1(4):508-15. doi: 10.3978/j.issn.2225-319X.2012.10.05. No abstract available. — View Citation

Soto-Ortiz L, Finley SD. A cancer treatment based on synergy between anti-angiogenic and immune cell therapies. J Theor Biol. 2016 Apr 7;394:197-211. doi: 10.1016/j.jtbi.2016.01.026. Epub 2016 Jan 27. — View Citation

Tsiouris A, Walesby RK. Malignant pleural mesothelioma: current concepts in treatment. Nat Clin Pract Oncol. 2007 Jun;4(6):344-52. doi: 10.1038/ncponc0839. — View Citation

Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003 Jul 15;21(14):2636-44. doi: 10.1200/JCO.2003.11.136. — View Citation

Wallin JJ, Bendell JC, Funke R, Sznol M, Korski K, Jones S, Hernandez G, Mier J, He X, Hodi FS, Denker M, Leveque V, Canamero M, Babitski G, Koeppen H, Ziai J, Sharma N, Gaire F, Chen DS, Waterkamp D, Hegde PS, McDermott DF. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun. 2016 Aug 30;7:12624. doi: 10.1038/ncomms12624. — View Citation

Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Riviere F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup (IFCT). Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016 Apr 2;387(10026):1405-1414. doi: 10.1016/S0140-6736(15)01238-6. Epub 2015 Dec 21. Erratum In: Lancet. 2016 Apr 2;387(10026):e24. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Survival (OS)	Overall survival is defined as the time from the date of randomisation until death from any cause. Data for patients who are not reported as having died at the date of analysis will be censored at the date when they were last known to be alive. Data for patients without post-baseline information will be censored at the date of randomization (plus 1 day).	From date of randomisation until death from any cause, assessed up to 58 months
Secondary	Progression-free Survival (PFS) according to the mRECIST v1.1	PFS is defined as the time from the date of randomisation until documented progression (according to the mRECIST v1.1) or death, if progression is not documented. Censoring (for participants without a PFS/death event) will occur at the date of last tumour assessment. Patients without a post-baseline tumour assessment will be censored at the date of randomization (plus 1 day).	From date of randomisation until documented progression or death, if progression is not documented, assessed up to 58 months
Secondary	Objective Response Rate (ORR)	Defined as the percentage of patients that achieve a best overall response [complete response (CR) or partial response (PR)] evaluated according to the mRECIST v1.1 across all post-randomization time-points until the end of protocol treatment or, as an alternative approach, until the end of follow-up. Confirmation of response will not be required.	From start of protocol treatment acorss all time-points until end of protocol treatment or, as an alternative approach, until the end of follow-up, assessed up to 58 months
Secondary	Disease Control (DC) at 24 weeks	Defined as complete or partial response, or disease stabilisation at 24 weeks.	24 weeks after protocol treatment start
Secondary	Time to Treatment Failure (TTF)	Defined as the time from the date of randomisation to discontinuation of protocol treatment for any reason (including progression of disease, death, discontinuation of at least one of the drugs consisting the treatment combination due to any reason, such as toxicity or refusal). Censoring will occur at the last follow-up date.	From randomisation until discontinuation of protocol treatment for any reason, assessed up to 58 months
Secondary	Duration of Response (DoR)	Defined as the interval from the date of first documentation of objective response (complete response or partial response, according to the mRECIST v1.1) to the date of first documented progression/ relapse or death.	From date of first documentation of objective response until date of first documented progression/ relapse or death, assessed up to 58 months
Secondary	Number of participants with treatment related adverse events according to Common Toxicity Criteria for Adverse Events (CTCAE) v5.0	Assessed through analysis of the worst grade of toxicity/adverse events and will include all participants who received at least one dose of protocol treatment. Adverse events leading to dose interruption, withdrawal of protocol treatment and deaths, laboratory parameters and abnormalities and vital signs over the whole treatment period will be assessed and graded according to CTCAE v5.0 criteria.	Assessed from the date of informed consent until 90 days after protocol treatment discontinuation. Analysed at 58 months after randomisation of the first patient